Receptor type I and type II binding regions and the peptidyl-prolyl isomerase site of cyclophilin B are required for enhancement of T-lymphocyte adhesion to fibronectin.
Cyclophilin B (CyPB), a cyclosporin A (CsA) binding protein, interacts with two types of binding sites at the surface of T-lymphocytes. The type I sites correspond to functional receptors involved in endocytosis and the type II sites to sulfated glycosaminoglycans (GAGs). Mutational analysis of CyPB has revealed that W128, which is part of the CsA-binding pocket, is implicated in the binding to the functional type I receptors and that two amino acid clusters located in the N-terminus ensure the binding to GAGs. The peptidyl-prolyl isomerase activity of CyPB is not required for receptor binding. We have recently demonstrated that CyPB enhances adhesion of peripheral blood T-lymphocytes to fibronectin, a component of the extracellular matrix. We intended to identify additional amino acids involved in the binding of CyPB to its functional type I receptor and to determine regions responsible for the stimulation of peripheral blood T-lymphocyte adhesion. We determined that residues R76, G77, K132, D155, and D158 of the calcineurin (CN) interacting region were implicated in the recognition of type I receptor but not of GAGs. We also found that two different changes in the N-terminal extension that abated binding to GAGs prevented adhesion of peripheral blood T-lymphocytes to coated CyPB, whereas abbrogation of the PPIase activity had no effect. On the other hand, the adhesion of peripheral blood T-lymphocytes to coated fibronectin was not stimulated by CyPB mutants devoid of either type I receptor or GAGs binding activity or by mutants of the PPIase site. Altogether, the results demonstrate that different regions of CyPB are involved in peripheral blood T-lymphocyte activation and imply a novel important physiological function for peptidyl-prolyl isomerase activity.
Carpentier
Mathieu
M
Laboratoire de Chimie Biologique, Unité Mixte de Recherche No. 8576 du Centre National de la Recherche Scientifique, IFR 118, Université des Sciences et Technologies de Lille, F-59655 Villeneuve d'Ascq Cedex, France.
Allain
Fabrice
F
Slomianny
Marie-Christine
MC
Durieux
Sandrine
S
Vanpouille
Christophe
C
Haendler
Bernard
B
Spik
Geneviève
G
D000276:Adjuvants, Immunologic / Q000097:blood / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D019943:Amino Acid Substitution / Q000235:genetics; D001665:Binding Sites / Q000235:genetics / Q000276:immunology; D001667:Binding, Competitive / Q000235:genetics / Q000276:immunology; D019703:Calcineurin / Q000378:metabolism; D002448:Cell Adhesion / Q000235:genetics / Q000276:immunology; D016572:Cyclosporine / Q000378:metabolism; D004705:Endocytosis / Q000502:physiology; D005353:Fibronectins / Q000378:metabolism* / Q000502:physiology; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D019169:Jurkat Cells; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism; D019696:Peptidylprolyl Isomerase / Q000378:metabolism* / Q000502:physiology; D011485:Protein Binding / Q000235:genetics / Q000276:immunology; D018000:Receptors, Peptide / Q000097:blood / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D013601:T-Lymphocytes / Q000201:enzymology* / Q000502:physiology
D000276:Adjuvants, Immunologic; D005353:Fibronectins; D006025:Glycosaminoglycans; D010446:Peptide Fragments; D018000:Receptors, Peptide; C100811:cyclophilin B receptor; D016572:Cyclosporine; D019703:Calcineurin; D019696:Peptidylprolyl Isomerase